دورية أكاديمية
أعرض في EDS

Real-World, Multicenter Case Series of Patients Treated with Oral Omadacycline for Resistant Gram-Negative Pathogens.

التفاصيل البيبلوغرافية
العنوان: Real-World, Multicenter Case Series of Patients Treated with Oral Omadacycline for Resistant Gram-Negative Pathogens.
المؤلفون: Morrisette T; Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, 259 Mack Avenue, Detroit, MI, 48201, USA.; Department of Clinical Pharmacy and Outcomes Sciences, Medical University of South Carolina College of Pharmacy, 280 Calhoun Street, Charleston, SC, 29425, USA.; Department of Clinical Pharmacy Services, Medical University of South Carolina Shawn Jenkins Children's Hospital, 10 McClennan Banks Drive, Charleston, SC, 29425, USA., Alosaimy S; Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, 259 Mack Avenue, Detroit, MI, 48201, USA., Lagnf AM; Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, 259 Mack Avenue, Detroit, MI, 48201, USA., Frens JJ; Department of Pharmacy, Cone Health, 1121 North Church Street, Greensboro, NC, 27401, USA., Webb AJ; Department of Pharmacy, Mayo Clinic, 200 1st Street SW, Rochester, MN, 55905, USA., Veve MP; University of Tennessee Medical Center, 1924 Alcoa Hwy, Knoxville, TN, 37920, USA.; Department of Clinical Pharmacy and Transplational Science, College of Pharmacy, University of Tennessee Health Science Center, 1924 Alcoa Hwy, Knoxville, TN, 37920, USA.; Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, 259 Mack Avenue, Detroit, MI, 48206, USA., Stevens R; Department of Pharmacy, Mayo Clinic, 200 1st Street SW, Rochester, MN, 55905, USA., Bouchard J; College of Pharmacy, University of South Carolina, 715 Sumter Street, Columbia, SC, 29208, USA., Gore TW; College of Pharmacy, University of South Carolina, 715 Sumter Street, Columbia, SC, 29208, USA., Ansari I; Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, 259 Mack Avenue, Detroit, MI, 48201, USA., Rybak MJ; Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, 259 Mack Avenue, Detroit, MI, 48201, USA. m.rybak@wayne.edu.; Division of Infectious Diseases, Department of Medicine, Wayne State University, 540 E Canfield Street, Detroit, MI, 48201, USA. m.rybak@wayne.edu.; Department of Pharmacy, Detroit Receiving Hospital, 4201 St Antoine, Detroit, MI, 48201, USA. m.rybak@wayne.edu.
المصدر: Infectious diseases and therapy [Infect Dis Ther] 2022 Aug; Vol. 11 (4), pp. 1715-1723. Date of Electronic Publication: 2022 May 14.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Adis Country of Publication: New Zealand NLM ID: 101634499 Publication Model: Print-Electronic Cited Medium: Print ISSN: 2193-8229 (Print) Linking ISSN: 21936382 NLM ISO Abbreviation: Infect Dis Ther Subsets: PubMed not MEDLINE
أسماء مطبوعة: Publication: 2014- : [Auckland] Adis
Original Publication: [London] : Springer Healthcare
مستخلص: Introduction: Antibiotic-resistant Gram-negative bacteria have been associated with substantial morbidity and mortality and have limited treatment options available. Omadacycline (OMC) is an aminomethylcycline antibiotic that has been shown to exhibit broad in vitro activity against antibiotic-resistant Gram-negative bacteria. Given the lack of real-world data, the primary objective of our report was to describe early experience with OMC for the treatment of resistant Gram-negative infections.
Methods: This was a real-world, multicenter, observational cases series/pilot study conducted in the USA. Inclusion criteria included any adult patient aged ≥ 18 years who received OMC for ≥ 72 h either in the inpatient and/or outpatient setting. Clinical success was defined as a composite of 90-day survival from initiation of OMC, lack of alteration in treatment/addition of other antibiotic due to concerns of OMC failure, and lack of microbiologic recurrence within 30 days from the end of therapy.
Results: Oral OMC was used in nine cases primarily for multidrug-resistant (MDR)/extensively drug-resistant (XDR) Gram-negative bacterial infections (55.6% XDR and/or carbapenem-resistant Acinetobacter baumannii [CRAB]). The majority of infections were of bone/joint (55.6%) origin, followed by intra-abdominal (33.3%) origin. Clinical success occurred in 66.7% of cases, with 80.0% success each in infections of bone/joint origin or those caused by CRAB. One patient experienced an adverse effect that was not treatment limiting while on therapy (gastrointestinal).
Conclusion: The use of oral OMC in MDR/XDR Gram-negative infections exhibited a relatively high success rate with minimal adverse effects. Real-world studies with larger case numbers are needed to confirm our initial findings.
(© 2022. The Author(s).)
References: Front Microbiol. 2019 Jan 30;10:80. (PMID: 30761114)
Antimicrob Agents Chemother. 2018 Jan 25;62(2):. (PMID: 29180524)
Antimicrob Agents Chemother. 2018 Mar 27;62(4):. (PMID: 29378719)
Open Forum Infect Dis. 2017 Aug 16;4(3):ofx176. (PMID: 29026867)
Antimicrob Agents Chemother. 2019 Jun 24;63(7):. (PMID: 31036691)
N Engl J Med. 2019 Jan 31;380(5):425-436. (PMID: 30699315)
Int J Antimicrob Agents. 2015 Jun;45(6):568-85. (PMID: 25857949)
Microb Drug Resist. 2021 Feb;27(2):190-195. (PMID: 32580619)
J Bone Jt Infect. 2020 Feb 21;5(2):60-66. (PMID: 32455096)
Diagn Microbiol Infect Dis. 2013 Feb;75(2):115-20. (PMID: 23290507)
J Antimicrob Chemother. 2021 Feb 11;76(3):667-670. (PMID: 33294925)
Lancet Infect Dis. 2019 Oct;19(10):1080-1090. (PMID: 31474458)
PLoS Med. 2015 May 19;12(5):e1001825. (PMID: 25992781)
Drugs. 2014 Aug;74(12):1315-33. (PMID: 25091170)
Clin Microbiol Infect. 2012 Mar;18(3):268-81. (PMID: 21793988)
Antimicrob Agents Chemother. 2014;58(3):1279-83. (PMID: 24041885)
N Engl J Med. 2019 Jan 31;380(5):415-424. (PMID: 30152252)
Antimicrob Agents Chemother. 2016 Dec 27;61(1):. (PMID: 27821446)
N Engl J Med. 2019 Feb 7;380(6):517-527. (PMID: 30726692)
Aust Prescr. 2020 Apr;43(2):45-48. (PMID: 32346210)
Antimicrob Agents Chemother. 2017 Apr 24;61(5):. (PMID: 28193651)
معلومات مُعتمدة: R01 AI121400 United States AI NIAID NIH HHS
فهرسة مساهمة: Keywords: Carbapenem-resistant Acinetobacter baumannii; Carbapenem-resistant Enterobacteriaceae; Gram-negative resistance; Omadacycline
تواريخ الأحداث: Date Created: 20220514 Latest Revision: 20220801
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC9334473
DOI: 10.1007/s40121-022-00645-5
PMID: 35567718
قاعدة البيانات: MEDLINE
الوصف
تدمد:2193-8229
DOI:10.1007/s40121-022-00645-5